• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小鼠肝炎病毒A59株刺突蛋白中融合肽样区域的突变分析

Mutational analysis of fusion peptide-like regions in the mouse hepatitis virus strain A59 spike protein.

作者信息

Luo Z L, Weiss S R

机构信息

Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.

出版信息

Adv Exp Med Biol. 1998;440:17-23. doi: 10.1007/978-1-4615-5331-1_3.

DOI:10.1007/978-1-4615-5331-1_3
PMID:9782260
Abstract

The coronavirus peplomer protein S is responsible for attachment and fusion during viral entry as well as for the induction of cell to cell fusion. While several regions within S have been shown to influence the ability to induce fusion, the region of the protein actually responsible for fusion, the fusion peptide, has not yet been identified. We identified two hydrophobic peptides (peptides #1 and #2) within MHV-A59 S2 as possible fusion domains. This was based on hydrophobicity, conservation among coronavirus S proteins and the prediction of a sided helix conformation. Using site directed mutagenesis and an in vitro cell to cell fusion assay we showed that substitution of hydrophobic amino acids with charged amino acids, within the predicted hydrophobic face of either of these two peptides eliminated fusion. Within peptide #1 substitution of the same hydrophobic amino acids with other hydrophobic amino acids or substitution of polar amino acids with charged or polar amino acids had little effect on fusion. Thus peptides #1 and #2 remain likely candidates for the MHV fusion peptide. A third previously identified peptide within S2 (Chambers et al., 1990) is unlikely as a fusion peptide as it is not well conserved among coronaviruses and substitution within the hydrophobic face with charged amino acids does not effect fusion.

摘要

冠状病毒纤突蛋白S负责病毒进入过程中的附着与融合以及细胞间融合的诱导。虽然已证明S蛋白内的几个区域会影响诱导融合的能力,但该蛋白中实际负责融合的区域,即融合肽,尚未确定。我们在MHV - A59 S2内鉴定出两个疏水肽(肽#1和肽#2)作为可能的融合结构域。这是基于疏水性、冠状病毒S蛋白之间的保守性以及对单侧螺旋构象的预测。使用定点诱变和体外细胞间融合试验,我们发现,在这两个肽中任一个的预测疏水面上,用带电荷氨基酸取代疏水氨基酸会消除融合。在肽#1中,用其他疏水氨基酸取代相同的疏水氨基酸,或用带电荷或极性氨基酸取代极性氨基酸,对融合影响很小。因此,肽#1和肽#2仍是MHV融合肽的可能候选者。先前在S2中鉴定出的第三个肽(Chambers等人,1990年)不太可能是融合肽,因为它在冠状病毒中保守性不佳,并且在疏水面上用带电荷氨基酸取代不会影响融合。

相似文献

1
Mutational analysis of fusion peptide-like regions in the mouse hepatitis virus strain A59 spike protein.小鼠肝炎病毒A59株刺突蛋白中融合肽样区域的突变分析
Adv Exp Med Biol. 1998;440:17-23. doi: 10.1007/978-1-4615-5331-1_3.
2
Roles in cell-to-cell fusion of two conserved hydrophobic regions in the murine coronavirus spike protein.小鼠冠状病毒刺突蛋白中两个保守疏水区域在细胞间融合中的作用。
Virology. 1998 May 10;244(2):483-94. doi: 10.1006/viro.1998.9121.
3
Identification of H209 as Essential for pH 8-Triggered Receptor-Independent Syncytium Formation by S Protein of Mouse Hepatitis Virus A59.鉴定 H209 是 A59 型鼠肝炎病毒 S 蛋白在 pH8 触发受体非依赖的合胞体形成所必需的。
J Virol. 2018 May 14;92(11). doi: 10.1128/JVI.00209-18. Print 2018 Jun 1.
4
Requirement of proteolytic cleavage of the murine coronavirus MHV-2 spike protein for fusion activity.鼠冠状病毒MHV-2刺突蛋白的蛋白水解切割对融合活性的需求。
Adv Exp Med Biol. 1998;440:89-93. doi: 10.1007/978-1-4615-5331-1_12.
5
The function of the spike protein of mouse hepatitis virus strain A59 can be studied on virus-like particles: cleavage is not required for infectivity.小鼠肝炎病毒A59株刺突蛋白的功能可在病毒样颗粒上进行研究:感染性并不需要蛋白裂解。
J Virol. 1997 Dec;71(12):9427-33. doi: 10.1128/JVI.71.12.9427-9433.1997.
6
Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core.冠状病毒介导膜融合的结构基础。小鼠肝炎病毒刺突蛋白融合核心的晶体结构。
J Biol Chem. 2004 Jul 16;279(29):30514-22. doi: 10.1074/jbc.M403760200. Epub 2004 Apr 27.
7
Coronavirus-induced membrane fusion requires the cysteine-rich domain in the spike protein.冠状病毒诱导的膜融合需要刺突蛋白中的富含半胱氨酸结构域。
Virology. 2000 Mar 30;269(1):212-24. doi: 10.1006/viro.2000.0219.
8
Murine coronavirus evolution in vivo: functional compensation of a detrimental amino acid substitution in the receptor binding domain of the spike glycoprotein.小鼠冠状病毒在体内的进化:刺突糖蛋白受体结合域中有害氨基酸取代的功能补偿
J Virol. 2005 Jun;79(12):7629-40. doi: 10.1128/JVI.79.12.7629-7640.2005.
9
Effects of amino acid insertions in the cysteine-rich domain of the MHV-A59 spike protein on cell fusion.在MHV - A59刺突蛋白富含半胱氨酸结构域中插入氨基酸对细胞融合的影响。
Adv Exp Med Biol. 2001;494:205-11. doi: 10.1007/978-1-4615-1325-4_33.
10
Mutational analysis of the murine coronavirus spike protein: effect on cell-to-cell fusion.鼠冠状病毒刺突蛋白的突变分析:对细胞间融合的影响。
Virology. 1995 Dec 20;214(2):453-63. doi: 10.1006/viro.1995.0056.

引用本文的文献

1
A proline insertion-deletion in the spike glycoprotein fusion peptide of mouse hepatitis virus strongly alters neuropathology.鼠肝炎病毒刺突糖蛋白融合肽中的脯氨酸插入缺失强烈改变神经病理学。
J Biol Chem. 2019 May 17;294(20):8064-8087. doi: 10.1074/jbc.RA118.004418. Epub 2019 Mar 1.
2
Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein.严重急性呼吸综合征相关冠状病毒刺突蛋白假定融合肽的鉴定与表征
J Virol. 2005 Jun;79(11):7195-206. doi: 10.1128/JVI.79.11.7195-7206.2005.
3
Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors.
遵循规则:严重急性呼吸综合征冠状病毒刺突蛋白融合核心6螺旋束的形成及强效肽抑制剂的鉴定。
Biochem Biophys Res Commun. 2004 Jun 18;319(1):283-8. doi: 10.1016/j.bbrc.2004.04.141.
4
Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor.严重急性呼吸综合征冠状病毒刺突蛋白的270至510位氨基酸是与受体相互作用所必需的。
J Virol. 2004 May;78(9):4552-60. doi: 10.1128/jvi.78.9.4552-4560.2004.
5
Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E.人冠状病毒HCoV-229E刺突糖蛋白受体结合结构域的鉴定
J Virol. 2003 Feb;77(4):2530-8. doi: 10.1128/jvi.77.4.2530-2538.2003.